Fig. 3From: Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresisa Erythroderma at diagnosis of aGVHD. b Regression of cutaneous aGVHD after 2 weeks of treatment with ruxolitinibBack to article page